Irritable Bowel Syndrome (IBD)

Categories: Gastrointestinal diseases

Aliases & Classifications for Irritable Bowel Syndrome

MalaCards integrated aliases for Irritable Bowel Syndrome:

Name: Irritable Bowel Syndrome 12 74 36 42 43 15 62 17 71 32
Ibd 12 3
Irritable Colon 12
Psychogenic Ibs 12


External Ids:

Disease Ontology 12 DOID:9778
KEGG 36 H01615
ICD9CM 34 564.1
MeSH 43 D043183
NCIt 49 C82343
SNOMED-CT 67 10743008
ICD10 32 K58 K58.0 K58.9
UMLS 71 C0022104

Summaries for Irritable Bowel Syndrome

KEGG : 36 Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder. It is characterized by symptoms of abdominal pain, bloating, and abnormal bowel movements, such as diarrhea or constipation. In IBS, there appears to be no organic substance or biochemical abnormality that can explain the symptoms. IBS can be classified into categories: constipation predominant IBS (IBS-C), diarrhea predominant IBS (IBS-D), mixed IBS (IBS-M), and un-subtyped IBS. Anticholinergic drugs, 5-HT3 receptor antagonist, high molecular weight polymers (polycarbophil calcium), gastrointestinal motility regulators, probiotics preparations, and laxatives are used in the treatment of IBS. However, they are not uniformly effective. Several studies of patients with IBS suggest that this disorder aggregates in families, and thus, appears potentially heritable. It has been reported that familial GUCY2C diarrhoea syndrome shares clinical characteristics with IBS-D.

MalaCards based summary : Irritable Bowel Syndrome, also known as ibd, is related to fibromyalgia and cyclic vomiting syndrome, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Irritable Bowel Syndrome is HTR3A (5-Hydroxytryptamine Receptor 3A), and among its related pathways/superpathways are Inflammatory bowel disease (IBD) and Peptide ligand-binding receptors. The drugs Pentoxifylline and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A syndrome that is a functional bowel disorder characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits in the absence of any detectable organic cause.

MedlinePlus : 42 Irritable bowel syndrome (IBS) is a problem that affects the large intestine. It can cause abdominal cramping, bloating, and a change in bowel habits. Some people with the disorder have constipation. Some have diarrhea. Others go back and forth between the two. Although IBS can cause a great deal of discomfort, it does not harm the intestines. IBS is common. It affects about twice as many women as men and is most often found in people younger than 45 years. No one knows the exact cause of IBS. There is no specific test for it. Your doctor may run tests to be sure you don't have other diseases. These tests may include stool sampling tests, blood tests, and x-rays. Your doctor may also do a test called a sigmoidoscopy or colonoscopy. Most people diagnosed with IBS can control their symptoms with diet, stress management, probiotics, and medicine. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn's disease. Inflammation affects the entire digestive tract in Crohn's disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body's immune system.

PubMed Health : 62 About irritable bowel syndrome: The typical symptoms of irritable bowel syndrome (IBS) include abdominal pain, constipation and diarrhea. Although IBS is not dangerous, the symptoms can be very painful and bothersome. Most people who have IBS have a mild form which they can cope with quite well without getting any treatment. But some people have symptoms that are so severe they significantly affect their everyday lives and cause distress. There is no cure for IBS. But over time, many people find out what helps and what makes things worse. And there are a number of different ways to relieve the symptoms.

Wikipedia : 74 Irritable bowel syndrome (IBS) is a group of symptoms-including abdominal pain and changes in the... more...

Related Diseases for Irritable Bowel Syndrome

Diseases related to Irritable Bowel Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 772)
# Related Disease Score Top Affiliating Genes
1 fibromyalgia 33.3 TNF SLC6A4 IL6 IL10 HTR3A CRH
2 cyclic vomiting syndrome 33.3 IL6 HTR3A
3 interstitial cystitis 33.0 TRPV1 TAC1 IL6
4 diarrhea 32.3 TNF TLR4 TGM2 TAC1 SLC6A4 PYY
5 gastroenteritis 32.1 TNF PYY MLN IL6 IL10
6 depression 32.0 SLC6A4 CRHR1 CRH
7 constipation 32.0 VIP TAC1 SLC6A4 PYY MLN HTR4
8 colitis 32.0 TNF TLR4 IL6 IL10
9 ulcerative colitis 31.9 TNF TLR4 IL6 IL10
10 crohn's disease 31.8 TNF TLR4 IL6 IL10
11 microscopic colitis 31.8 TNF TGM2 SLC6A4 IL6
12 food allergy 31.7 TNF TLR4 IL10
13 generalized anxiety disorder 31.7 TPH1 SLC6A4 HTR3A CRHR1
14 dysentery 31.7 TNF TLR4 IL6 IL10
15 celiac disease 1 31.6 TNF TLR4 TGM2 PYY IL6 IL10
16 sclerosing cholangitis 31.6 TNF TLR4 IL6 IL10
17 cholangitis 31.6 TNF TLR4 IL6 IL10
18 gastroesophageal reflux 31.6 VIP TNF PYY MLN IL6 CCK
19 acute stress disorder 31.5 SLC6A4 CRHR1 CRH
20 sleep disorder 31.5 TNF SLC6A4 IL6
21 inflammatory bowel disease 31.4 VIP TNF TLR4 TAC1 PYY IL6
22 somatization disorder 31.4 TAC1 SLC6A4 CRH
23 mood disorder 31.4 TPH1 SLC6A4 IL6 HTR3A CRHR2 CRHR1
24 eating disorder 31.3 SLC6A4 PYY CRHR2 CRH CCK
25 esophagitis 31.3 TNF IL6 IL10
26 proteasome-associated autoinflammatory syndrome 1 31.3 TNF TLR4 IL6 IL10
27 chickenpox 31.2 TNF IL6 IL10
28 prostatitis 31.2 TNF IL6 IL10
29 spondylitis 31.2 TNF IL6 IL10
30 chronic fatigue syndrome 31.2 TNF TLR4 SLC6A4 IL6 IL10 HTR3A
31 bacterial infectious disease 31.2 TNF TLR4 IL6 IL10
32 gastritis 31.2 TNF TLR4 IL6 IL10
33 dermatitis 31.2 TNF TLR4 IL6 IL10
34 rhinitis 31.2 VIP TNF IL6 IL10
35 gastrointestinal system disease 31.2 MLN MIR24-1 HTR4 CCK
36 acute cystitis 31.2 TNF TLR4 IL6 IL10
37 exanthem 31.1 TNF IL6 IL10
38 gastroparesis 31.1 MLN HTR3A CCK
39 social phobia 31.1 SLC6A4 HTR3A CCK
40 phobic disorder 31.1 SLC6A4 CRHR1 CRH
41 functional colonic disease 31.1 VIP MLN
42 chlamydia 31.1 TNF TLR4 IL6 IL10
43 shigellosis 31.1 TNF TLR4 IL10
44 herpes zoster 31.1 TRPV1 TNF IL10
45 duodenogastric reflux 31.0 PYY MLN CCK
46 leptin deficiency or dysfunction 31.0 TNF PYY IL6 CCK
47 mental depression 31.0 TPH1 SLC6A4 MIR24-1 IL6 HTR3A CRHR1
48 contact dermatitis 31.0 TNF TLR4 IL6 IL10
49 bipolar disorder 30.9 TPH1 TNF SLC6A4 IL6 HTR3A CRHR1
50 somatoform disorder 30.9 TRPV1 TPH1 TAC1 SLC6A4 HTR3A

Comorbidity relations with Irritable Bowel Syndrome via Phenotypic Disease Network (PDN): (show all 24)

Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Anxiety
Atrophic Gastritis Bronchitis
Deficiency Anemia Dependent Personality Disorder
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Generalized Anxiety Disorder
Hypertension, Essential Hypochondriasis
Hypothyroidism Intermediate Coronary Syndrome
Intestinal Obstruction Iron Deficiency Anemia
Major Depressive Disorder Mitral Valve Disease
Osteoporosis Paralytic Ileus
Protein-Energy Malnutrition Somatization Disorder

Graphical network of the top 20 diseases related to Irritable Bowel Syndrome:

Diseases related to Irritable Bowel Syndrome

Symptoms & Phenotypes for Irritable Bowel Syndrome

UMLS symptoms related to Irritable Bowel Syndrome:

nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas, vomiting following gastrointestinal surgery

MGI Mouse Phenotypes related to Irritable Bowel Syndrome:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 CRH CRHR1 CRHR2 HTR3A HTR4 IL10
2 homeostasis/metabolism MP:0005376 10.27 CCK CRH CRHR1 CRHR2 HTR3A HTR4
3 cardiovascular system MP:0005385 10.23 CRHR1 CRHR2 IL10 IL6 SLC6A4 TAC1
4 growth/size/body region MP:0005378 10.18 CRH HTR3A HTR4 IL10 IL6 PYY
5 endocrine/exocrine gland MP:0005379 10.17 CCK CRH CRHR1 CRHR2 HTR3A IL10
6 adipose tissue MP:0005375 10.15 CRH CRHR2 HTR4 IL6 PYY TLR4
7 nervous system MP:0003631 10.07 CCK CRH CRHR1 HTR3A HTR4 IL10
8 integument MP:0010771 10.02 CRH HTR3A IL10 IL6 SLC6A4 TAC1
9 no phenotypic analysis MP:0003012 9.7 CCK CRH CRHR1 IL10 TGM2 TNF
10 renal/urinary system MP:0005367 9.56 CCK CRH HTR3A IL6 TAC1 TGM2
11 respiratory system MP:0005388 9.28 CRH CRHR1 HTR4 IL10 IL6 TLR4

Drugs & Therapeutics for Irritable Bowel Syndrome

PubMed Health treatment related to Irritable Bowel Syndrome: 62

There are a lot of different opinions about what can help relieve irritable bowel syndrome . Common recommendations include eating or avoiding certain foods and getting exercise . But most of this advice has not been tested in good-quality studies. If you ask different people who have IBS, it becomes clear that something that helps one person may end up making someone else’s symptoms worse. So it is best to try out different things and see for yourself if it helps. For example, someone who thinks that a particular type of food is making their symptoms worse can try to avoid eating it for a while. Some people have fewer symptoms if they eat their meals in smaller portions throughout the day. Keeping a diary can help you figure out whether doing specific things like exercising more or avoiding certain types of food have any effect. You can make a note of what you eat, how physically active you are, and how stressed you are over a longer period of time. It might be possible to recognize patterns after a while. There are also a number of different treatments that aim to relieve the symptoms. Because the causes of IBS are not clear, it is difficult to find suitable treatments. But research has suggested that at least some medications and treatments may help. Treatments for IBS include: Fiber supplements, for instance made from psyllium Peppermint oil Probiotics Anti-cramping medications Medications for constipation or diarrhea Various medications, such as antibiotics or antidepressants Psychological treatments , such as stress management or hypnosis Because medications in particular can have a number of side effects and sometimes even make the symptoms worse, it is worth carefully considering the potential advantages and disadvantages of taking them.

Drugs for Irritable Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 401)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
Alverine Approved, Investigational Phase 4 150-59-4 3678
Linaclotide Approved Phase 4 851199-59-2 65351
Histamine Approved, Investigational Phase 4 51-45-6 774
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
Trimebutine Approved Phase 4 39133-31-8
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
Secretin Approved Phase 4 108153-74-8
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
Drospirenone Approved Phase 4 67392-87-4 68873
Dienogest Approved Phase 4 65928-58-7
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
Colestipol Approved Phase 4 26658-42-4
Lactulose Approved Phase 4 4618-18-2 11333
Citalopram Approved Phase 4 59729-33-8 2771
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Tiropramide Investigational Phase 4 55837-29-1 42262
32 Rebamipide Investigational Phase 4 90098-04-7
Ramosetron Investigational Phase 4 132036-88-5
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
35 Fenoverine Investigational Phase 4 37561-27-6
Daidzein Experimental Phase 4 486-66-8 5281708
Genistein Investigational Phase 4 446-72-0 5280961
Nandrolone Experimental, Investigational Phase 4 434-22-0 9904
39 Octylonium Phase 4
40 Guar Phase 4
41 Protective Agents Phase 4
42 Antioxidants Phase 4
43 Free Radical Scavengers Phase 4
44 Vasodilator Agents Phase 4
45 Phosphodiesterase Inhibitors Phase 4
46 Radiation-Protective Agents Phase 4
47 BB 1101 Phase 4
48 Cyclooxygenase Inhibitors Phase 4
49 Cyclooxygenase 2 Inhibitors Phase 4
50 Corticotropin-Releasing Hormone Phase 4

Interventional clinical trials:

(show top 50) (show all 864)
# Name Status NCT ID Phase Drugs
1 Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome: A Randomized, Double-blinded,Placebo- Controlled Multicenter Study Unknown status NCT02614963 Phase 4 Clostridium Butyricum;placebo
2 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
3 Comparative and Analytical Study for Effectiveness and Safety of Tiropramide HCl and Octylonium Bromide in the Treatment of Irritable Bowel Syndrome: Mullticenter, Randomized, Double Blind, Active Controlled Study Unknown status NCT01629212 Phase 4 Tiropramide HCl 100mg;Octylonium bromide 20mg
4 Peripheral Histamine 1 Receptor Blockade in IBS Unknown status NCT01908465 Phase 4 Ebastine;Placebo
5 Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome Unknown status NCT02565550 Phase 4
6 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome- a Double Blind, Placebo - Controlled, Randomized Study Unknown status NCT01779765 Phase 4
7 Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
8 Effect of Pentoxifylline on Tight Junctions of Intestinal Mucosa in Patients With Irritable Bowel Syndrome Unknown status NCT01542268 Phase 4 pentoxifylline;pentoxifylline placebo
9 Efficacy of Proklama on Patients' Symptoms With Irritable Bowel Syndrome: Clinical Trial, Double- Blind, Crossover, Controlled Study vs. Placebo Unknown status NCT02573844 Phase 4 Proklama
10 Effect of a Mixture of Probiotics, Lactibiane Tolérance® on Intestinal Permeability in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance Unknown status NCT02728063 Phase 4
11 Spectrum of Gastrointestinal Microbiota in Patients With IBS-D Before and After Treatment With VSL#3. Unknown status NCT01638208 Phase 4 VSL#3
12 Effect of Ramosetron on Postoperative Restoration of Bowel Motility After Gynecological Laparoscopic Surgery Unknown status NCT02849483 Phase 4 Ramosetron;Normal saline
13 Effect of Ramosetron on Bowel Motility and PONV After Laparoscopic Stomach and Colorectal Resection Unknown status NCT01427127 Phase 4 Ramosetron
14 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
15 Assessment of Analgesic Efficacy and Safety of Intravenous Hyoscine-N-Butylbromide in Patients With Abdominal Colic Associated With Acute Gastroenteritis; a Randomized, Double-blind, Placebo Controlled Study Unknown status NCT02508142 Phase 4 Hyoscine-N-Butylbromide
16 Prospective, Interventional, Single Arm Study in Outpatients Undergoing Sigmoidoscopy for Evaluation of Efficacy and Safety of Kleen Enema 120ml (Phosphate Enema) Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
17 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
18 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
19 Study Title: Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial Completed NCT00779493 Phase 4
20 A Randomize, Placebo-controlled, Crossover Study to Measure the Effect of Alosetron on Mucosal Blood Flow in Female Healthy Volunteers and Diarrhea-predominant IBS Subjects Completed NCT00370032 Phase 4 alosetron
21 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT01225237 Phase 4 Ramosetron;Placebo
22 Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome. a 4-Week, Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase IV Trial Completed NCT00542295 Phase 4 alverine citrate and simeticone;placebo
23 Assessment of On-demand MeteoSpasmyl® Use Effectiveness in Irritable Bowel Syndrome Completed NCT01404923 Phase 4 anti spasmodic agents;alverine citrate, simeticone
24 A Phase 4, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation Completed NCT02837783 Phase 4 Linaclotide;Placebo
25 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4 Ramosetron;Placebo
26 Randomized Controlled Trial of Escitalopram Versus Placebo for Patients With Irritable Bowel Syndrome and Panic Disorder Completed NCT01551225 Phase 4 Escitalopram
27 IBS Treatment With H1-receptor Antagonists Completed NCT01144832 Phase 4 ebastine;placebo capsule
28 Valutazione Dell'Efficacia Di Una Preparazione Commerciale A Base Di Lactobacillus Casei Dg Nella Riduzione Della Sintomatologia Dolorosa Associata Alla Sindrome Dell' Intestino Irritabile (Sii). Studio Clinico Pilota. (Official Title in Italian Language) Completed NCT02077699 Phase 4
29 Randomised Controlled Trial: Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome Completed NCT01886781 Phase 4 Lactobacillus plantarum 299v;Placebo comparator
30 A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel Group Study to Assess Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms With Prior Loperamide Use (RELIEF) Completed NCT02959983 Phase 4 Eluxadoline;Placebo
31 Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D). Completed NCT01316718 Phase 4 Mesalazine;Placebo
32 Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression Completed NCT01754493 Phase 4 Duloxetine
33 Efficacy Evaluation of Enterogermina, 2 Billion Bacillus Clausii Spores, on Eradication of Small Intestinal Bacterial Overgrowth: a Randomised, Parallel-group, Open Study. Completed NCT00331994 Phase 4 Bacillus clausii;Metronidazole
34 An Open-label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation. Completed NCT02590432 Phase 4 Linaclotide
35 Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS Completed NCT00142987 Phase 4 Tegaserod
36 Comparative Efficacy and Safety of Fenoverine and Trimebutine Maleate in Irritable Bowel Syndrome; A Randomized Double-blind Parallel Multi-center Phase IV Trial Completed NCT01507922 Phase 4 Fenoverine;Timebutine
37 Ability of Mayo Clinic HPLC Method to Measure Fecal Bile Acids to Demonstrate Response to Colesevelam in Patients With Diarrhea Predominant Irritable Bowel Syndrome Completed NCT02111603 Phase 4 Colesevelam
38 Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS) Completed NCT00693732 Phase 4 Escitalopram treatment
39 Efficacy of the Combination Therapy With Alverine-simeticone and i3.1 Probiotic Formula in the Quality of Life of Patients With IBS-D or IBS-M in Hospital Juarez Mexico Completed NCT04145856 Phase 4
40 An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Without Comorbid Major Depressive Disorder Completed NCT00401258 Phase 4 duloxetine
41 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
42 Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome Completed NCT02026518 Phase 4
43 Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D): Identifying the "Responder" Completed NCT00745004 Phase 4 Ondansetron;Placebo
44 Supplementation With a Multi-strain Probiotic Formulation (Bio-Kult®) in the Management of Diarrhea-predominant Irritable Bowel Syndrome - a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT03251625 Phase 4 Probiotic Formula Capsule
45 Management of Irritable Bowel Syndrome in Primary Care: Feasibility Randomised Controlled Trial of Mebeverine, Methylcellulose, Placebo and a Patient Self-management Cognitive Behavioural Therapy Website. (MIBS Trial) Completed NCT00934973 Phase 4 mebeverine;methylcellulose;placebo
46 Effect of Pregabalin on Colonic Motor and Sensory Function in Adults With Irritable Bowel Syndrome With Predominant Constipation Completed NCT01331213 Phase 4 Pregabalin;Placebo
47 Irritable Bowel Syndrome Evaluation and Treatment in Primary Care Completed NCT01641341 Phase 4 Bifidobacterium infantis;Pancrelipase;Nitazoxanide;Placebo
48 Glucomannn for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Randomized Double Blind Placebo Controlled Trial Completed NCT01495806 Phase 4 Glucomannan;placebo
49 Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications Completed NCT01096290 Phase 4 lubiprostone;Matched placebo
50 A Multicentre, Randomised, Double-Blind, Placebo Controlled, Crossover Trial On The Efficacy Of A Mixture Of Three Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders Completed NCT02566876 Phase 4 Mixture of three Bifidobacteria

Search NIH Clinical Center for Irritable Bowel Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :

alosetron hydrochloride
calcium polycarbophil
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
Propantheline Bromide
Tegaserod maleate

Cochrane evidence based reviews: irritable bowel syndrome

Genetic Tests for Irritable Bowel Syndrome

Anatomical Context for Irritable Bowel Syndrome

MalaCards organs/tissues related to Irritable Bowel Syndrome:

Colon, Testes, Brain, Small Intestine, Liver, Heart, Bone

Publications for Irritable Bowel Syndrome

Articles related to Irritable Bowel Syndrome:

(show top 50) (show all 12403)
# Title Authors PMID Year
The Rome IV: Irritable bowel syndrome - A functional disorder. 61 42
31594650 2019
Pathophysiology of the irritable bowel syndrome - Reflections of today. 61 42
31594651 2019
Pseudo-obstruction, enteric dysmotility and irritable bowel syndrome. 61 42
31594655 2019
The gut microbiome as a predictor of low fermentable oligosaccharides disaccharides monosaccharides and polyols diet efficacy in functional bowel disorders. 61
31850930 2020
Maternal separation in rodents: a journey from gut to brain and nutritional perspectives. 61
31250784 2020
Lactose and Fructo-oligosaccharides Increase Visceral Sensitivity in Mice via Glycation Processes, Increasing Mast Cell Density in Colonic Mucosa. 61
31711923 2020
Abdominal Pain in Children Develops With Age and Increases With Psychosocial Factors. 61
31009796 2020
Determination of subtypes of Blastocystis sp. in Chilean patients with and without inflammatory bowel syndrome, A preliminary report. 61
31890923 2020
Association between gastrointestinal complaints and psychopathology in patients with anorexia nervosa. 61
32040232 2020
Plecanatide for the treatment of constipation-predominant irritable bowel syndrome. 61
31985305 2020
Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS). 61
31727345 2020
Traditional treatments for irritable bowel syndrome: the state of our knowledge. 61
31859184 2020
Epidemiology of irritable bowel syndrome and its associated factors in Saudi undergraduate students. 61
32031159 2020
Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey. 61
31711922 2020
Increased Gut Permeability in First-degree Relatives of Children with Irritable Bowel Syndrome or Functional Abdominal Pain. 61
31100459 2020
Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double-blind, placebo-controlled trial. 61
31486103 2020
Benefits and Pitfalls of Change From Rome III to Rome IV Criteria for Irritable Bowel Syndrome and Fecal Incontinence. 61
31606457 2020
Chronic Gastrointestinal and Joint-Related Sequelae Associated with Common Foodborne Illnesses: A Scoping Review. 61
31589475 2020
Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis. 61
32009472 2020
Irritable bowel syndrome and gut microbiota. 61
31789724 2020
Microbiome and Its Role in Irritable Bowel Syndrome. 61
32026278 2020
Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. 61
31913194 2020
Relationships of Microbiome Markers With Extraintestinal, Psychological Distress and Gastrointestinal Symptoms, and Quality of Life in Women With Irritable Bowel Syndrome. 61
30148765 2020
The Glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome. 61
31602785 2020
Presentation and Characteristics of Abdominal Pain Vary by Irritable Bowel Syndrome Subtype: Results of a Nationwide Population-Based Study. 61
31913193 2020
Similarities in Clinical and Psychosocial Characteristics of Functional Diarrhea and Irritable Bowel Syndrome With Diarrhea. 61
31442602 2020
Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria. 61
31154027 2020
Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. 61
32010878 2020
Peroxiredoxin 1 as an inflammatory marker in diarrhea-predominant and postinfectious irritable bowel syndrome. 61
31613423 2020
Evaluating When and Why Patients Discontinue Chronic Therapy for Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation. 61
32022721 2020
Effectiveness of Sterilized Symbiotic Drink Containing Lactobacillus helveticus Comparable to Probiotic Alone in Patients with Constipation-Predominant Irritable Bowel Syndrome. 61
31209720 2020
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1). 61
31934897 2020
Association of Intestinal Disorders with Parkinson's Disease and Alzheimer's Disease: A Systematic Review and Meta-Analysis. 61
31876406 2020
The impact of allergic rhinitis on gastrointestinal disorders among young adults. 61
30773746 2020
Functional somatic illnesses in patients with functional bowel disorders. A cross-sectional cohort study in western Saudi Arabia. 61
32020157 2020
Does a Minority of Children With Functional Gastrointestinal Disorders Receive Formal Diet Advice? 61
32017170 2020
The association between irritable bowel syndrome and osteoporosis: a systematic review and meta-analysis. 61
32008157 2020
Electro-Neuromodulation for Colonic Disorders-Review of Meta-Analyses, Systematic Reviews, and RCTs. 61
32017319 2020
Sucrase-Isomaltase Deficiency as a Potential Masquerader in Irritable Bowel Syndrome. 61
31493040 2020
Group cognitive behavioural therapy (GCBT) versus treatment as usual (TAU) in the treatment of irritable bowel syndrome (IBS): a study protocol for a randomized controlled trial. 61
32019509 2020
Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. 61
31859183 2020
Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D: Additional post hoc analyses of Phase 3 trials. 61
31984655 2020
The Potential of Integrated Nurse-Led Models to Improve Care for People With Functional Gastrointestinal Disorders: A Systematic Review. 61
31990873 2020
Brain orexin improves intestinal barrier function via the vagal cholinergic pathway. 61
31678432 2020
Enterocolic increase of cannabinoid receptor type 1 and type 2 and clinical improvement after probiotic administration in dogs with chronic signs of colonic dysmotility without mucosal inflammatory changes. 61
31495983 2020
Adrenergic Signaling in Muscularis Macrophages Limits Infection-Induced Neuronal Loss. 61
31923400 2020
Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. 61
31960952 2020
Chronic Diseases, Health Conditions, and Other Impacts Associated With Rape Victimization of U.S. Women. 61
31971055 2020
Laparoscopic treatment of a pericaecal internal hernia. 61
31929229 2020
Exploitation of Drosophila Choriogenesis Process as a Model Cellular System for Assessment of Compound Toxicity: the Phloroglucinol Paradigm. 61
31937877 2020

Variations for Irritable Bowel Syndrome

Expression for Irritable Bowel Syndrome

Search GEO for disease gene expression data for Irritable Bowel Syndrome.

Pathways for Irritable Bowel Syndrome

Pathways related to Irritable Bowel Syndrome according to KEGG:

# Name Kegg Source Accession
1 Inflammatory bowel disease (IBD) hsa05321

Pathways related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
Show member pathways
3 12.13 TNF TLR4 IL6 IL10
Show member pathways
11.96 TNF TLR4 IL6 IL10
6 11.92 TNF TLR4 IL6 IL10
7 11.82 TNF TLR4 IL6 IL10
8 11.78 TPH1 SLC6A4 HTR4 HTR3E HTR3A
9 11.76 TLR4 CRHR2 CRHR1 CRH
10 11.65 TNF IL6 IL10
11 11.64 TNF TLR4 IL6 IL10
12 11.59 TNF TGM2 IL6 IL10
13 11.52 TNF TLR4 IL6
14 11.43 TNF IL6 IL10
15 11.38 TPH1 TNF TAC1 SLC6A4 IL6 IL10
16 11.37 TNF TLR4 IL6 IL10
17 11.3 TNF IL6 IL10
18 11.16 TNF IL6 IL10
19 11 TNF TLR4 IL6 IL10
20 10.7 TPH1 SLC6A4 HTR4 HTR3A
21 10.44 VIP CCK
22 10.28 CRHR2 CRHR1 CRH

GO Terms for Irritable Bowel Syndrome

Cellular components related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 VIP TNF TAC1 PYY MLN IL6
2 extracellular space GO:0005615 10.01 TNF TAC1 PYY MIR24-1 IL6 IL10
3 synapse GO:0045202 9.8 TRPV1 TAC1 SLC6A4 HTR4 HTR3E HTR3A
4 neuronal cell body GO:0043025 9.72 TRPV1 TAC1 HTR3A CRH CCK
5 neuron projection GO:0043005 9.63 VIP TRPV1 TPH1 SLC6A4 HTR3E HTR3A
6 integral component of plasma membrane GO:0005887 9.61 TRPV1 TNF TLR4 SLC6A4 HTR4 HTR3E
7 intrinsic component of plasma membrane GO:0031226 8.92 TRPV1 TLR4 TGM2 CRHR1

Biological processes related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.04 TNF TLR4 IL6 IL10 CRHR1
2 positive regulation of gene expression GO:0010628 10.01 TNF TLR4 SLC6A4 IL6 CRH
3 positive regulation of apoptotic process GO:0043065 9.93 TRPV1 TNF TGM2 IL6 CCK
4 cellular response to lipopolysaccharide GO:0071222 9.86 TNF TLR4 IL6 IL10
5 positive regulation of inflammatory response GO:0050729 9.83 TNF TLR4 TGM2
6 G protein-coupled receptor signaling pathway GO:0007186 9.81 VIP TAC1 PYY MLN HTR4 CRHR2
7 chemical synaptic transmission GO:0007268 9.8 TAC1 HTR4 HTR3E HTR3A CRH
8 response to glucocorticoid GO:0051384 9.78 TNF IL6 IL10
9 positive regulation of interleukin-6 production GO:0032755 9.77 TNF TLR4 IL6
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.76 TNF TGM2 IL6
11 signal transduction GO:0007165 9.7 VIP TLR4 IL6 IL10 HTR4 HTR3E
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.69 TRPV1 TNF TLR4
13 negative regulation of interleukin-6 production GO:0032715 9.67 TNF TLR4 IL10
14 positive regulation of neuroinflammatory response GO:0150078 9.65 TNF IL6
15 negative regulation of heart rate GO:0010459 9.64 TRPV1 TAC1
16 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 TLR4 IL10
17 parturition GO:0007567 9.63 CRHR1 CRH
18 regulation of sensory perception of pain GO:0051930 9.63 VIP IL10 CCK
19 negative regulation of lipid storage GO:0010888 9.62 TNF IL6
20 serotonin receptor signaling pathway GO:0007210 9.62 HTR3E HTR3A
21 positive regulation of JAK-STAT cascade GO:0046427 9.61 TNF IL6 IL10
22 endothelial cell apoptotic process GO:0072577 9.6 TNF IL10
23 positive regulation of behavioral fear response GO:2000987 9.58 CRH CCK
24 positive regulation of lymphocyte proliferation GO:0050671 9.57 TLR4 TAC1
25 negative regulation of cytokine secretion involved in immune response GO:0002740 9.55 TNF IL10
26 cellular response to corticotropin-releasing hormone stimulus GO:0071376 9.52 CRHR2 CRHR1
27 response to pain GO:0048265 9.5 TRPV1 TAC1 CRH
28 receptor biosynthetic process GO:0032800 9.48 TNF IL10
29 positive regulation of chemokine production GO:0032722 9.43 TNF TLR4 IL6
30 positive regulation of corticosterone secretion GO:2000854 9.37 TAC1 CRH
31 inflammatory response GO:0006954 9.17 TRPV1 TNF TLR4 TAC1 IL6 IL10

Molecular functions related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.71 TRPV1 TLR4 HTR3E HTR3A
2 extracellular ligand-gated ion channel activity GO:0005230 9.54 TRPV1 HTR3E HTR3A
3 peptide hormone receptor binding GO:0051428 9.46 VIP CCK
4 serotonin binding GO:0051378 9.43 SLC6A4 HTR3A
5 hormone activity GO:0005179 9.35 VIP PYY MLN CRH CCK
6 serotonin-gated cation-selective channel activity GO:0022850 9.32 HTR3E HTR3A
7 corticotropin-releasing hormone receptor activity GO:0043404 9.26 CRHR2 CRHR1
8 corticotrophin-releasing factor receptor activity GO:0015056 9.16 CRHR2 CRHR1
9 neuropeptide hormone activity GO:0005184 8.92 VIP PYY CRH CCK

Sources for Irritable Bowel Syndrome

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....